Related Experiment Video
Updated: Jun 23, 2026
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Tim P Green1, Mike Fennell, Robin Whittaker
1Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK. timgreen350@googlemail.com
Abstract:
AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive effects in vitro, and inhibited metastasis in a murine model of bladder cancer. Antiproliferative activity of AZD0530 in vitro varied between cell lines (IC(50) 0.2 ->10μM). AZD0530 inhibited tumor growth in 4/10 xenograft models tested and dynamically inhibited in vivo phosphorylation of Src substrates paxillin and FAK in both growth-inhibition-resistant and -sensitive xenografts. The activity of AZD0530 in NBT-II bladder cancer cells in vitro was consistent with inhibition of cell migration and stabilization of cell-cell adhesion. These data suggest a dominant anti-invasive pharmacology for AZD0530 that may limit tumor progression in a range of cancers. AZD0530 is currently in Phase II clinical trials.
Insights
AZD0530, a Src inhibitor, effectively reduced cancer cell migration and invasion in lab studies and animal models. This drug shows promise in limiting tumor progression and metastasis across various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Src kinases are critical regulators of cell migration, invasion, and survival.
- Dysregulation of Src signaling is implicated in various human cancers, making it a therapeutic target.
- Developing orally available Src inhibitors offers a promising strategy for cancer treatment.
Purpose of the Study:
- To evaluate the antimigratory, anti-invasive, and antitumor effects of AZD0530, an orally available Src inhibitor.
- To investigate the in vitro and in vivo mechanisms of action of AZD0530 in cancer models.
- To assess the potential of AZD0530 in limiting tumor progression and metastasis.
Main Methods:
- In vitro assays assessing cell proliferation, migration, and invasion using various cancer cell lines.
- In vivo studies using a murine model of bladder cancer and xenograft models.
- Western blot analysis to measure the in vivo phosphorylation of Src substrates (paxillin and FAK).
Main Results:
- AZD0530 demonstrated potent in vitro antimigratory and anti-invasive effects, with varying antiproliferative activity (IC(50) 0.2-10μM).
- The drug inhibited metastasis in a murine bladder cancer model and tumor growth in 4/10 xenograft models.
- AZD0530 dynamically inhibited in vivo phosphorylation of paxillin and FAK in both sensitive and resistant xenografts, confirming target engagement.
Conclusions:
- AZD0530 exhibits a dominant anti-invasive pharmacology, suggesting its potential to limit tumor progression.
- The Src inhibitor AZD0530 shows therapeutic potential in a range of cancers by targeting key pathways involved in invasion and metastasis.
- These findings support the ongoing clinical evaluation of AZD0530 in Phase II trials.